Vericel Corp. buy melinda
Start price
01.04.13
/
50%
€11.74
Target price
01.10.13
€14.00
Performance (%)
-70.70%
End price
01.10.13
€3.44
Summary
This prediction ended on 01.10.13 with a price of €3.44. Massive losses of -70.70% were the result for the BUY prediction by melinda. melinda has a follow-up prediction for Vericel Corp. where he still thinks Vericel Corp. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Vericel Corp. | -6.912% | -6.912% | 20.238% | -7.339% |
iShares Core DAX® | 1.395% | -0.696% | 15.472% | 15.907% |
iShares Nasdaq 100 | 2.287% | 7.501% | 34.748% | 53.474% |
iShares Nikkei 225® | 1.617% | 2.769% | 11.442% | 8.194% |
iShares S&P 500 | 0.659% | 4.280% | 26.778% | 45.322% |
According to melinda what are the pros and cons of Vericel Corp. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Vericel Corp. diskutieren
Biosciences
Aastrom Biosciences plötzlichen Temperaturabfall nicht -45% Erholung kommt bald
(Laufzeit überschritten)
Current prediction by melinda for Vericel Corp.
Vericel Corp.
Start price
Target price
Perf. (%)
€30.20
19.08.23
19.08.23
-
19.08.24
19.08.24
39.07%
04.07.24
04.07.24
Could be worthwhile Investment >10% per year
Stopped prediction by melinda for Vericel Corp.
Vericel Corp.
Start price
Target price
Perf. (%)
€10.85
11.03.20
11.03.20
€15.00
04.11.21
04.11.21
288.94%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Vericel Corp.
Start price
Target price
Perf. (%)
€4.42
07.10.17
07.10.17
€5.41
03.01.18
03.01.18
20.41%
03.01.18
03.01.18
Could be worthwhile Investment >10% per year
Vericel Corp.
Start price
Target price
Perf. (%)
€2.85
23.04.16
23.04.16
€4.96
24.10.16
24.10.16
-22.47%
24.10.16
24.10.16
Could be worthwhile Investment >10% per year
Vericel Corp.
Start price
Target price
Perf. (%)
€49.92
11.01.11
11.01.11
€80.00
11.07.11
11.07.11
-24.88%
11.07.11
11.07.11
Could be worthwhile Investment >10% per year